STERIS (NYSE:STE) Given “Market Outperform” Rating at JMP Securities

STERIS (NYSE:STE)‘s stock had its “market outperform” rating reaffirmed by equities researchers at JMP Securities in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $265.00 price target on the medical equipment provider’s stock. JMP Securities’ price target suggests a potential upside of 18.76% from the company’s previous close.

Several other research firms also recently weighed in on STE. StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Stephens reiterated an “overweight” rating and set a $240.00 price target on shares of STERIS in a research note on Thursday. Piper Sandler lifted their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $258.75.

STERIS Price Performance

Shares of NYSE:STE opened at $223.13 on Thursday. STERIS has a 12 month low of $197.82 and a 12 month high of $248.24. The firm has a market capitalization of $22.03 billion, a P/E ratio of 50.94 and a beta of 0.84. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. The company’s fifty day moving average price is $212.49 and its 200 day moving average price is $224.60.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.78% and a net margin of 8.02%. As a group, sell-side analysts predict that STERIS will post 9.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.14% of the stock is currently owned by corporate insiders.

Institutional Trading of STERIS

A number of institutional investors have recently modified their holdings of STE. Geode Capital Management LLC lifted its holdings in STERIS by 0.7% in the third quarter. Geode Capital Management LLC now owns 2,303,625 shares of the medical equipment provider’s stock valued at $556,786,000 after acquiring an additional 17,007 shares during the period. Principal Financial Group Inc. boosted its holdings in STERIS by 0.5% during the fourth quarter. Principal Financial Group Inc. now owns 1,119,643 shares of the medical equipment provider’s stock worth $230,160,000 after buying an additional 5,419 shares in the last quarter. Raymond James Financial Inc. acquired a new position in STERIS during the fourth quarter worth about $223,987,000. Franklin Resources Inc. increased its holdings in STERIS by 171.2% in the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after buying an additional 529,308 shares in the last quarter. Finally, Raymond James & Associates lifted its position in shares of STERIS by 1.5% during the 3rd quarter. Raymond James & Associates now owns 801,144 shares of the medical equipment provider’s stock valued at $194,309,000 after acquiring an additional 12,005 shares during the period. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.